Form 4: Intra-Cellular Therapies Executive Halstead Reports Stock Transactions

Michael Halstead, President of Intra-Cellular Therapies, reports acquisition of shares through vested restricted stock units and disposition of shares to cover tax obligations.

Summary

• On January 31, 2025, Michael Halstead, President of Intra-Cellular Therapies, acquired 11,017 shares of common stock upon vesting of performance-based restricted stock units (PRSUs).
• The shares were acquired at a price of $0.
• On the same day, Halstead disposed of 5,691 shares to satisfy tax withholding obligations at a price of $127 per share.
• Following these transactions, Halstead directly owns 5,326 shares of Intra-Cellular Therapies common stock.
• On February 3, 2025, Halstead was granted 45,454 restricted stock units (RSUs) that vest in three equal annual installments beginning on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to stock-based compensation and tax obligations. There is no indication of unusual or concerning activity.

Positives

• The vesting of performance-based restricted stock units indicates that Halstead met certain performance criteria.

Negatives

• The disposition of shares to cover tax obligations reduces Halstead's overall holdings in the company.

Future Outlook

The granted restricted stock units will vest in three equal annual installments beginning on February 3, 2026.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry to align the interests of executives with those of shareholders.
• Vesting schedules and performance-based criteria are typical features of equity incentive plans in comparable companies such as Eli Lilly, Pfizer, and AbbVie.
• The specific number of shares and vesting terms are company-specific and depend on factors such as company size, performance, and executive compensation policies.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The vesting of equity awards aligns management's interests with those of shareholders.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Restricted Stock Units, ITCI, Intra-Cellular Therapies, Beneficial Ownership, Halstead Michael